News Category
Newron Pharmaceuticals has received FDA feedback on a clinical hold at U.S. sites for its Phase 3 ENIGMA-TRS 2 study and is preparing a response while...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher's clinical research business to execute a Phase 2 trial of Lucid-MS, a firs...
Quantum BioPharma's agreement with Thermo Fisher's clinical research business moves its lead multiple sclerosis drug Lucid-MS into a phase 2 trial, te...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to execute a Phase 2 trial of Lucid...
XORTX Therapeutics is advancing XORLO, a proprietary oxypurinol formulation for gout, toward a New Drug Application with the FDA, potentially offering...
Quantum BioPharma's agreement with Thermo Fisher for its Phase 2 Lucid-MS trial marks a critical step toward developing a first-in-class treatment for...
NanoViricides will present at the NIBA 153rd Investment Conference on Oct. 7, 2026, showcasing its broad-spectrum antiviral NV-387, which is in Phase ...
Quantum BioPharma's Study Start-Up Agreement with Thermo Fisher for its Phase 2 Lucid-MS trial signals a critical step toward developing a first-in-cl...
India's drug regulator has cleared Okogen's Phase 1/2 EMERALD study of Treyegen, a single therapy targeting both viral and bacterial conjunctivitis, p...
NanoViricides has provided an update on its Phase II clinical trial of NV-387 Oral Gummies for Ebola, highlighting the potential of an oral antiviral ...
Nutriband Inc. celebrates its fifth anniversary on the Nasdaq Capital Market with a shareholder letter detailing the advancement of its abuse-deterren...
Gianluca Cerri, MD, is advocating for a personal policy that ensures every opioid use disorder patient in a rural emergency department receives a same...
Stonegate Capital Partners' updated coverage highlights Incannex Healthcare's progress in clinical execution and the implications for its lead asset I...
AAG Zacheriel's debut novel, The Vena Protocol: First Blood, uses fiction to spotlight the critical issue of clinical trial data integrity and its imp...
Quantum BioPharma's Lucid-MS is entering a Phase 2 trial in multiple sclerosis patients, while the company also holds a 20% stake and a 7% royalty str...
Quantum BioPharma's Lucid-MS multiple sclerosis drug advances to Phase 2 testing while its alcohol metabolism product unbuzzd(TM) offers a 7% royalty ...
A new NFID survey reveals that while 77% of US adults support vaccines, only 48% got vaccinated against respiratory diseases in the past year, highlig...
NanoViricides, Inc. (NYSE American: NNVC) has received regulatory approval to begin Phase II trials of NV-387 Oral Gummies for Mpox and Ebola in the D...
NanoViricides has begun patient enrollment and dosing in a Phase II trial of NV-387 Oral Gummies for Bundibugyo Ebolavirus in the Democratic Republic ...
Quantum BioPharma's FDA IND approval for Lucid-MS marks a pivotal step toward a phase 2 trial of a novel multiple sclerosis treatment with a unique me...
Nutriband Inc. has appointed former Navy SEAL Robert J. O’Neill to its Advisory Board to help advance its abuse-deterrent transdermal products, includ...
Creative Biolabs has introduced a three-part antibody engineering framework to help biopharmaceutical researchers overcome immunogenicity, efficacy, a...
FamiCord AG's CDMO division Bramble Bio will establish GMP manufacturing for VERIGRAFT's personalized tissue-engineered vein P-TEV in an 18-month deal...
Quantum BioPharma (NASDAQ: QNTM) has received FDA approval of its IND application for Lucid-MS, enabling phase 2 clinical testing of a novel multiple ...
Annovis Bio's collaboration with Weave Bio to use AI for drafting its buntanetap NDA could speed regulatory submission and strengthen its position in ...
The American Heart Association will award its 2026 Clinical Research Prize to Dr. Katherine R. Tuttle for her pioneering research that has fundamental...
Boston BioLife marks 11 years of bridging science and clinical medicine by co-presenting the Translational Longevity Summit, aiming to accelerate resp...
Tonix Pharmaceuticals' second major managed Medicare agreement for TONMYA adds approximately 21 million covered lives, bringing total Medicare coverag...
In vitro ADME studies provide critical early insights into drug candidates' behavior, reducing costly late-stage failures and accelerating development...
A new study reveals that the risk of sepsis, meningitis, and pneumonia from air pollution depends on individual bacterial strains, highlighting the ne...
Peptide Wholesale Supply now provides HPLC chromatographic data for each batch of BPC-157, Semaglutide, and Tirzepatide bulk orders, enhancing analyti...
Experts urge small cell lung cancer patients to ask about clinical trials at their first appointment, as emerging research expands treatment options a...
GeoVax's agreement with CEPI to use its Centralised Laboratory Network for independent testing of GEO-MVA could accelerate the vaccine's development a...
Creative Biolabs has expanded its functionalized lipid-based delivery system development to help researchers address stability, targeting, and control...
BioCorRx Inc. appointed Richard J. Baum, former Acting Director of the White House Office of National Drug Control Policy, to its Strategic Advisory B...
Preclinical research published in Science Advances demonstrates that engineered suppressor tRNAs can restore full-length dystrophin and improve muscle...
Regentis Biomaterials reported first-half 2026 results, highlighting progress in its Phase III GelrinC trial, expanded clinical networks, and a new ma...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protecting drug, receives FDA clearance for a Phase 2 trial in multiple sclerosis, potentially o...
Regentis Biomaterials is developing GelrinC, an off-the-shelf hydrogel implant designed to regenerate knee cartilage, which could significantly improv...
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer signals a strategic push to advance its BiTAC® T-cell engager and broa...
Quantum BioPharma's Lucid-MS, a first-in-class non-covalent PAD2 inhibitor, is advancing to a Phase 2 trial for multiple sclerosis after FDA clearance...
Quantum BioPharma receives FDA clearance for the first-ever phase 2 trial of a myelin-rebuilding drug for multiple sclerosis, a potential game-changer...
Quantum BioPharma's FDA clearance to test Lucid-MS, a first-in-class multiple sclerosis drug designed to shield and rebuild myelin, marks a historic d...
Helus Pharma's CEO will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference, providing a platform to highlight the compa...
Onco-Innovations' CMO discussed the company's lead drug candidate ONC010, which targets PNKP and uses two selectivity mechanisms, and its potential to...
Quantum BioPharma's FDA clearance to begin a Phase 2 trial of Lucid-MS, a first-in-class non-covalent PAD2 inhibitor, positions the company to potenti...
An expert highlights significant flaws in standard UTI diagnostic methods, leading to misdiagnosis and recurrent infections, underscoring the urgent n...
Silo Pharma's participation in the IPAC-RS 2026 Nasal Innovation Forum underscores its commitment to advancing SPC-15, a nose-to-brain PTSD treatment,...
